Alten R, Lorenz H-M, Mariette X, et al. Abatacept retention rates and prognostic factors of retention in patients with rheumatoid arthritis: 2-year results from the real-world ACTION study. EULAR 2017, FRI0245.
Bimekizumab behaalt als eerste primair eindpunt ASAS40-respons na 12 weken
jun 2018 | Spondyloartritis